FR2985429B1 - Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle - Google Patents

Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle

Info

Publication number
FR2985429B1
FR2985429B1 FR1250224A FR1250224A FR2985429B1 FR 2985429 B1 FR2985429 B1 FR 2985429B1 FR 1250224 A FR1250224 A FR 1250224A FR 1250224 A FR1250224 A FR 1250224A FR 2985429 B1 FR2985429 B1 FR 2985429B1
Authority
FR
France
Prior art keywords
polymerization process
injectable solution
controlled polymerization
basic insulin
polyaminoacid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1250224A
Other languages
English (en)
Other versions
FR2985429A1 (fr
Inventor
Olivier Soula
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adocia SAS
Original Assignee
Adocia SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1250224A priority Critical patent/FR2985429B1/fr
Application filed by Adocia SAS filed Critical Adocia SAS
Priority to CN201710727572.3A priority patent/CN107583039A/zh
Priority to PCT/FR2013/050043 priority patent/WO2013104861A1/fr
Priority to US13/737,353 priority patent/US9198971B2/en
Priority to EP13701849.5A priority patent/EP2814461B1/fr
Priority to CN201380009297.1A priority patent/CN104114155B/zh
Priority to CN202111083637.8A priority patent/CN113730555A/zh
Priority to BR112014016889A priority patent/BR112014016889A8/pt
Publication of FR2985429A1 publication Critical patent/FR2985429A1/fr
Priority to US14/922,663 priority patent/US10335489B2/en
Application granted granted Critical
Publication of FR2985429B1 publication Critical patent/FR2985429B1/fr
Priority to HK18108633.6A priority patent/HK1248607A1/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR1250224A 2012-01-09 2012-01-09 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle Expired - Fee Related FR2985429B1 (fr)

Priority Applications (10)

Application Number Priority Date Filing Date Title
FR1250224A FR2985429B1 (fr) 2012-01-09 2012-01-09 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle
BR112014016889A BR112014016889A8 (pt) 2012-01-09 2013-01-09 composição sob a forma de uma solução aquosa injetável, sujo ph está compreendido entre 6,0 e 8,0 e, formulação de dose unitária com ph compreendido entre 7 e 7,8
US13/737,353 US9198971B2 (en) 2012-01-09 2013-01-09 Injectable solution at pH 7 comprising at least one basal insulin the pI of which is between 5.8 and 8.5 and a substituted co-polyamino acid
EP13701849.5A EP2814461B1 (fr) 2012-01-09 2013-01-09 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
CN201380009297.1A CN104114155B (zh) 2012-01-09 2013-01-09 Ph为7并且至少包含pi为5.8至8.5之基础胰岛素和经取代共聚(氨基酸)的可注射溶液
CN202111083637.8A CN113730555A (zh) 2012-01-09 2013-01-09 Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
CN201710727572.3A CN107583039A (zh) 2012-01-09 2013-01-09 Ph为7且至少含pi为5.8至8.5之基础胰岛素和取代共聚(氨基酸)的可注射溶液
PCT/FR2013/050043 WO2013104861A1 (fr) 2012-01-09 2013-01-09 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
US14/922,663 US10335489B2 (en) 2012-01-09 2015-10-26 Injectable solution at pH 7 comprising at least one basal insulin the pi of which is between 5.8 and 8.5 and a substituted co-polyamino acid
HK18108633.6A HK1248607A1 (zh) 2012-01-09 2018-07-04 Ph為7且至少含pi為5．8至8．5之基礎胰島素和取代共聚(氨基酸)的可注射溶液

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1250224A FR2985429B1 (fr) 2012-01-09 2012-01-09 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle

Publications (2)

Publication Number Publication Date
FR2985429A1 FR2985429A1 (fr) 2013-07-12
FR2985429B1 true FR2985429B1 (fr) 2016-07-29

Family

ID=46489322

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1250224A Expired - Fee Related FR2985429B1 (fr) 2012-01-09 2012-01-09 Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle

Country Status (1)

Country Link
FR (1) FR2985429B1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2578460C2 (ru) 2011-08-10 2016-03-27 Адосиа Приемлемый для инъекций раствор по меньшей мере одного базального инсулина
EP2814461B1 (fr) 2012-01-09 2019-07-24 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide substitue
US20150314003A2 (en) 2012-08-09 2015-11-05 Adocia Injectable solution at ph 7 comprising at least one basal insulin the isoelectric point of which is between 5.8 and 8.5 and a hydrophobized anionic polymer
FR3001895B1 (fr) * 2013-02-12 2015-07-03 Adocia Solution injectable a ph7 comprenant au moins une insuline basale dont le point isoelectrique est compris en 5,8 et 8,5 et un compose anionique porteur de charges carboxylates et de radicaux hydrophobes
FR3052072A1 (fr) 2016-06-07 2017-12-08 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
WO2018122278A1 (fr) * 2016-12-27 2018-07-05 Adocia Compositions sous forme de solution aqueuse injectable comprenant de l'amyline, un agoniste au récepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3061023B1 (fr) * 2016-12-27 2020-02-28 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3074680B1 (fr) * 2017-12-07 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
FR3074682B1 (fr) * 2017-12-07 2020-01-03 Adocia Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un co-polyaminoacide
CN111565710A (zh) * 2017-12-07 2020-08-21 阿道恰公司 包含胰淀素、胰淀素受体激动剂或胰淀素类似物以及共聚氨基酸的呈可注射水溶液形式的组合物
SG11202005322RA (en) 2017-12-07 2020-07-29 Adocia Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
CN111683674A (zh) 2017-12-07 2020-09-18 阿道恰公司 包含胰淀素、胰淀素激动剂受体或胰淀素类似物和共聚氨基酸的可注射水溶液形式的组合物
MA51127A (fr) * 2017-12-07 2021-03-17 Adocia Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2840614B1 (fr) * 2002-06-07 2004-08-27 Flamel Tech Sa Polyaminoacides fonctionnalises par de l'alpha-tocopherol et leurs applications notamment therapeutiques
CA2508751A1 (fr) * 2002-12-04 2004-07-22 Flamel Technologies Polyaminoacides fonctionnalises par au moins un groupement (oligo)aminoacide et leurs applications notamment therapeutiques
FR2862536B1 (fr) * 2003-11-21 2007-11-23 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
FR2902007B1 (fr) * 2006-06-09 2012-01-13 Flamel Tech Sa Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s) ainsi que leurs applications notamment therapeutiques
PL2597103T3 (pl) * 2007-11-16 2017-04-28 Novo Nordisk A/S Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
AU2011202239C1 (en) * 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins

Also Published As

Publication number Publication date
FR2985429A1 (fr) 2013-07-12

Similar Documents

Publication Publication Date Title
FR2985429B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue obtenu par un procede de polymerisation controle
FR2985428B1 (fr) Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un polyaminoacide substitue
EP4218487A3 (fr) Tige supérieure
BR112013006817A2 (pt) método, casquilho e casquilho formado pelo método
FR2997097B1 (fr) Procede de fabrication d'une fibre de carbone, materiau precurseur utilise par le procede et fibre de carbone obtenue.
MX367754B (es) Método para producir membranas de poliimida.
SG11201506035SA (en) High-concentration vanadium electrolytic solution, and method and device for producing the same
FR3043678B1 (fr) Procede de preparation d'un caoutchouc naturel stabilise.
FR3006943B1 (fr) Procede de realisation d'un berceau avant de vehicule, et berceau avant de vehicule obtenu par ce procede.
BR112015020838A2 (pt) processo para a preparação de poliamidas, poliamida e uso de uma poliamida.
JP2013541099A5 (fr)
MY166459A (en) Jointing and/or adhesive-bonding method and products produced in this way
PL3310636T3 (pl) Układ napędowy dla pojazdu szynowego, pojazd szynowy z układem napędowym oraz sposób wytwarzania układu napędowego i pojazdu szynowego
IN2013MU03124A (fr)
PL2843261T3 (pl) Napinacz cięgna, wibracyjna zgrzewarka z napinaczem cięgna, a także sposób wytwarzania napinacza cięgna
FR3027601B1 (fr) Procede de fonctionnalisation d'un polydiene au moyen d'une faible teneur en catalyseur de metathese
BR112013018974A2 (pt) processo melhorado para a preparação de 2,2-difluoroetilamina.
PT3062632T (pt) Polímero de fenol com ligações biarilo 5,5¿, método para a preparação do mesmo e seus usos
FR3003564B1 (fr) Procede de metathese comprenant l'extraction de l'ethylene forme au moyen d'une membrane
FR3001170B1 (fr) Procede preparatoire, par grands deplacements, a la mise au point d'une gamme de polissage par tribofinition
FR3030406B1 (fr) Fixation d'un enrouleur de ceinture de securite sur le pied milieu du vehicule, renforcee transversalement.
FR2978918B1 (fr) Solution injectable a ph7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5
FR3037852B1 (fr) Procede d'obtention d'un element de renforcement et d'assemblage de cet element a une piece a renforcer, par thermosoudage
BR112016021874A2 (pt) processo para preparar derivados de 3,5-bis(haloalquil)pirazol a partir de a,a-diholoaminas e cetiminas.
MX2013015418A (es) Bomba de una pieza con bisagra.

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 5

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 9

ST Notification of lapse

Effective date: 20210905